K562/Adr

Cat.No.: CSC-C6619J

Species: Homo sapiens (Human)

Source: Pleural Effusion

Morphology: Lymphocyte-like

Culture Properties: Suspension

  • Specification
  • Background
  • Scientific Data
  • Q & A
  • Customer Review
Cat.No.
CSC-C6619J
Description
Subline of K562. Resistant to adriamycin.
Species
Homo sapiens (Human)
Source
Pleural Effusion
Recommended Medium
Culture Properties
Suspension
Morphology
Lymphocyte-like
Disease
Chronic Myeloid Leukemia
Storage and Shipping
Storage condition: Liuqid Nitrogen, -180°C
Shipping: Dry Ice, Frozen
Synonyms
K562/adr; K-562adr; K562adr; K562/ADM
Citation Guidance
If you use this products in your scientific publication, it should be cited in the publication as: Creative Bioarray cat no. If your paper has been published, please click here to submit the PubMed ID of your paper to get a coupon.

K562/Adr is an Adriamycin (doxorubicin) resistant subline of the human chronic myelogenous leukemia (CML) cell line K562. The K562 cell line was isolated from the bone marrow of a patient with chronic myelogenous leukemia (CML) in blast crisis, and K562/Adr was generated from K562 by stepwise or continuous exposure to Adriamycin, resulting in a stable, high-level multidrug resistant subline. Morphologically, K562/Adr cells are suspension-growing cells with round/oval morphology and prominent nuclei and nucleoli. These cells phenotypically resemble the parent cell line and display hematopoietic progenitor-like morphology.

K562/Adr cells display overexpression of P-glycoprotein (MDR1/ABCB1) efflux transporter. It has been used as an in vitro model of multidrug resistance (MDR) in leukemia, for studying the molecular mechanisms of chemoresistance, and for screening novel anti-cancer agents or MDR inhibitors. K562/Adr has been used to study the mechanisms and inhibition of drug transporters and apoptotic/survival signaling pathways in drug resistant leukemia, for screening of small molecules and drugs, and for gene silencing or editing of genes related to drug resistance.

Effect of Low-Dose Radiation on the Kinetics of Pirarubicin and Daunorubicin Transport in K562 Cells and Drug Resistant K562/adr Cells

Low-dose radiation may affect drug transport kinetics. Here, Supawat et al. irradiated K562 and K562/adr cells with 137Cs gamma radiation at doses of 0, 0.02, 0.05, and 0.1 mGy and assessed cell viability and Pira/Dau transport kinetics at 0, 1, 4, and 24 hours post-irradiation.

Figure 1 A-F show the OD at 570 nm values in K562 and K562/adr cells collected at 0, 1, 4, and 24 h after in vitro exposure to various low doses of gamma radiation, followed by treatment with Pira and Dau. The OD at 570 nm indicates cell viability. At 0 h post-irradiation, significant changes in OD at 570 nm were observed in 0.1 mGy-irradiated K562/adr cells compared to non-irradiated K562/adr cells (Fig. 1D). Significant changes in OD at 570 nm were seen in irradiated K562/adr cells at 24 h post-irradiation compared to 0 h post-irradiation, while no significant changes were observed at 1 and 4 h post-irradiation (Fig. 1D). Significant changes in OD at 570 nm were also observed at 1, 4, and 24 h post-irradiation in 0.02 mGy-irradiated K562/adr cells treated with Pira compared to 0 h post-irradiation. Similarly, significant changes were seen at 24 h post-irradiation in 0.05 and 0.1 mGy-irradiated K562/adr cells treated with Pira compared to 0 h post-irradiation (Fig. 1E). At 0 h post-irradiation, significant changes in OD at 570 nm were observed in 0.1 mGy-irradiated K562/adr cells treated with Dau compared to non-irradiated K562 cells treated with Dau. Significant changes in OD at 570 nm were also seen at 24 h post-irradiation in 0.05 and 0.1 mGy-irradiated K562/adr cells treated with Dau compared to 0 h post-irradiation (Fig. 1F).

OD. at 570 nm values in K562 and K562/adr cells collected at 0, 1, 4, and 24 h after an in vitro exposure to various low doses of gamma radiation.

Fig. 1. OD. at 570 nm values in K562 and K562/adr cells collected at 0, 1, 4, and 24 h after an in vitro exposure to various low doses of gamma radiation (Supawat B, Kothan S, et al., 2024).

Ask a Question

Write your own review

  • You May Also Need

For research use only. Not for any other purpose.

Hot Products